Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension Domains

• Главные авторы: Martin Siegemund (Автор), Prajakta Oak (Автор), Eva-Maria Hansbauer (Автор), Andrea Allersdorfer (Автор), Karoline Utschick (Автор), Alexandra Winter (Автор), Christina Grasmüller (Автор), Gunther Galler (Автор), Jan-Peter Mayer (Автор), Benjamin Weiche (Автор), Josef Prassler (Автор), Roland E. Kontermann (Автор), Christine Rothe (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Anticalin® proteins have been proven as versatile clinical stage biotherapeutics. Due to their small size (∼20 kDa), they harbor a short intrinsic plasma half-life which can be extended, e.g., by fusion with IgG or Fc. However, for antagonism of co-immunostimulatory Tumor Necrosis Factor Receptor Su...